AQR Capital Management
LYEL icon

AQR Capital Management’s Lyell Immunopharma LYEL Stock Holding History

AQR Capital Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-8,714
Closed -$93.8K – 3346
2025
Q1 		$93.8K Buy
8,714
+7,716
+773% +$94.5K ﹤0.01% 3024
2024
Q4 		$12.8K Sell
998
-4,858
-83% -$96.3K ﹤0.01% 2853
2024
Q3 		$162K Buy
+5,856
New +$172K ﹤0.01% 2608
2024
Q2 		– Sell
-2,212
Closed -$98.7K – 2645
2024
Q1 		$98.7K Buy
2,212
+700
+46% +$30K ﹤0.01% 2341
2023
Q4 		$58.7K Buy
1,512
+33
+2% +$1.19K ﹤0.01% 2305
2023
Q3 		$43.5K Buy
+1,479
New +$70.2K ﹤0.01% 2289

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

AQR Capital Management's LYEL Position: Q2 2025 in Review

AQR Capital Management sold out of Lyell Immunopharma (LYEL) in Q2 2025, closing a stake of 8,714 shares — an estimated $93.8K sold.

AQR Capital Management first reported a position in LYEL in Q3 2023 and held it in 6 quarters. The position peaked at $162K in Q3 2024. 69 funds tracked by Wall St. Rank hold LYEL as of Q2 2025.

  • AQR Capital Management reported no remaining Lyell Immunopharma position as of Q2 2025 after selling out during the quarter.
  • AQR Capital Management sold 8,714 Lyell Immunopharma shares in Q2 2025, an estimated $93.8K.
  • AQR Capital Management first reported a position in Lyell Immunopharma in Q3 2023 and held it in 6 quarters.
  • AQR Capital Management's Lyell Immunopharma position peaked at $162K in Q3 2024.
  • 69 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2025.

Based on AQR Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.